Aligned Genetics Inc

Aligned Genetics Inc maintains a strong liquidity position, with a current ratio of 4.24, indicating the company can easily cover its short-term liabilities with its current assets. The company's cash and equivalents amount to KRW 4,410,909,450, while its long-term debt is KRW 4,614,016,730, resulting in a net cash position that is negative after subtracting total debt. This suggests the company may need to manage its debt obligations carefully to maintain its liquidity.

In terms of profitability, Aligned Genetics Inc has a return on equity (ROE) of 1.96% and a return on assets (ROA) of 1.5%, which are below the industry median for Advanced Medical Equipment & Technology. These figures suggest the company is not generating returns as efficiently as its peers. The company's operating income of KRW 201,065,490 and net income of KRW 626,917,880 indicate a profitable business, but the ROE and ROA figures suggest there is room for improvement in asset utilization and equity returns.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher risk if demand in its primary market fluctuates.

Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the company's free cash flow of KRW 772,140,220 and capital expenditure of KRW -10,597,490 suggest a relatively stable capital structure with minimal investment in new projects. This could indicate a conservative approach to growth or a focus on maintaining current operations.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of a negative net cash position after subtracting total debt suggests the company may need to manage its debt obligations carefully to avoid liquidity constraints. There is no indication of dilution potential in the basic shares outstanding, as the number of basic and diluted shares is the same.

Recent events, such as filings and transcripts, are not detailed in the available data. However, the company's financial statements and risk assessment provide a snapshot of its current financial health and risk profile.

Return on equity of 1.96% remains positive, outperforming the negative cohort median of -4.7% despite recent earnings volatility.

Capital expenditure intensity is low at -0.3% of revenue, placing it in the top quartile for capital efficiency.

Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity value from share issuance.

Long-term debt surged to 14.5 billion KRW, nearly quintupling from the prior period, increasing financial leverage risk.

Return on invested capital is merely 0.55%, indicating very poor efficiency in generating returns from capital employed.

Cash conversion ratio of 0.46 falls below the cohort median of 0.79, highlighting weaker cash generation relative to earnings.

Revenue KRW 15.21B, +10,6% YoY; Operating income +17,1% YoY.

• ▍Revenue KRW 15.21B, +10,6% YoY
• ▍Operating income +17,1% YoY
• ▍Net income +38,7% YoY
• ▍Free cash flow +159,2% YoY
• ▍Net margin 21.3%